| Literature DB >> 24550784 |
Abstract
The diversity of GABAA receptor (GABAAR) subunits and the numerous configurations during subunit assembly give rise to a variety of receptors with different functional properties. This heterogeneity results in variations in GABAergic conductances across numerous brain regions and cell types. Phasic inhibition is mediated by synaptically-localized receptors with a low affinity for GABA and results in a transient, rapidly desensitizing GABAergic conductance; whereas, tonic inhibition is mediated by extrasynaptic receptors with a high affinity for GABA and results in a persistent GABAergic conductance. The specific functions of tonic versus phasic GABAergic inhibition in different cell types and the impact on specific neural circuits are only beginning to be unraveled. Here we review the diversity in the magnitude of tonic GABAergic inhibition in various brain regions and cell types, and highlight the impact on neuronal excitability in different neuronal circuits. Further, we discuss the relevance of tonic inhibition in various physiological and pathological contexts as well as the potential of targeting these receptor subtypes for treatment of diseases, such as epilepsy.Entities:
Keywords: GABA; epilepsy; neuronal excitability; neurosteroids; tonic inhibition
Mesh:
Substances:
Year: 2014 PMID: 24550784 PMCID: PMC3909947 DOI: 10.3389/fncir.2014.00003
Source DB: PubMed Journal: Front Neural Circuits ISSN: 1662-5110 Impact factor: 3.492
Levels of tonic inhibition vary across brain region and cell type in the CNS.
| Dentate gyrus | ||||
| 12.8 ± 3.0 pA | BIC (100–150) or GBZ (100–150) | α4 | Nusser and Mody, | |
| 47.6 ± 10.1 pA | NO-711 (2.5) + BIC (100–150) or GBZ (100–150) | |||
| Rat (Wistar), >3 month; high Cl− internal; 34–36°C; KYN (3000–5000) | ||||
| 7.4 ± 1.1 pA | NO-711 (10) + GBZ (100–200); 13–29 day male | δ | Stell and Mody, | |
| 43.8 ± 10.8 pS/pF | NO-711 (10) + GBZ (100–200); 30–181 day male; –60 mV | |||
| Mouse (C57Bl/6); high Cl− internal; 33–35°C; KYN (3000–5000) | ||||
| 172.4 ± 51.4 pS/pF | GABA (5) + GBZ (>100); male | δ | Maguire et al., | |
| 29.8 ± 5.5 pS/pF | GABA (5) + GBZ (>100); 10–14 week female, estrus | |||
| 57.6 ± 10.2 pS/pF | GABA (5) + GBZ (>100); 10–14 week female, diestrus | |||
| Mouse (C57Bl/6); −60 mV; high Cl− internal; KYN (3000) | ||||
| 72 ± 19 pA n.s. | BIC (100) | Mtchedlishvili and Kapur, | ||
| GBZ (100) | ||||
| Rat (Sprague–Dawley), adult male; −65 mV; high Cl− internal; 20–22°C; AP5 (50), CNQX (20) | ||||
| 29.5 ± 5.4 pA | GABA (5) + GBZ (>100) | δ, γ | Zhang et al., | |
| Mouse (C57Bl/6), 30–60 day male; −70 mV; high Cl− internal; 35°C; KYN (3000–5000) | ||||
| 22.0 ± 5.33 pA | GABA (5) + BIC | δ, α5 | Glykys et al., | |
| Mouse (C57Bl/6), >35d male; −70 mV; high Cl− internal; 32–34°C; KYN (3000) | ||||
| 16.6 ± 2.7 pA | BIC (30) | α4β2δ, α5β1/3γ2 | Herd et al., | |
| Mouse (mixed), 20–26 day; −60 mV; high Cl− internal; 35°C; KYN (2000), TTX (0.5) | ||||
| 1.4 ± 0.3 pA | GBZ (100); rat (Sprague–Dawley), male | Zhan and Nadler, | ||
| 0.5 ± 0.2 pA | GBZ (100); mouse (C57Bl/6), >18 week male | |||
| −70 mV; high Cl− internal; 34–35°C; AP5 (50), NBQX (10) | ||||
| 8.4 ± 1.1 pA | BIC (100) | α4βδ | Gupta et al., | |
| 0.15 ± 0.03 pA/pF | Rat (Wistar), 4–5 week male; –70 mV; high Cl− internal; 33°C; KYN (3000) | |||
| 11.9 ± 1.5 pA | PTX (100) | Wlodarczyk et al., | ||
| 10.6 ± 3.6 pA | PTZ (1500) | |||
| 5.9 ± 0.6 pA | BIC (10) | |||
| −6.7 ± 1.6 pA | GBZ (125) | |||
| Rat (Sprague–Dawley), 3–4 week; –70 mV; high Cl− internal; 35°C; AP5 (50), NBQX (20), MCPG (250), CGP55845 (1) | ||||
| 3.36 ± 0.43 pA | BIC (20); Wistar | δ | Pandit et al., | |
| 1.74 ± 0.35 pA | BIC (20); Noda epileptic rat | |||
| 17.32 ± 3.56 pA | GABA (3) + BIC (20); Wistar | |||
| 8.86 ± 1.55 pA | GABA (3) + BIC (20); Noda epileptic rat | |||
| 28.28 ± 3.53 pA | NO-711 (5) + BIC (20); Wistar | |||
| 14.56 ± 3.41 pA | NO-711 (5) + BIC (20); Noda epileptic rat | |||
| Rat, 8 week male; –70 mV; high Cl− internal; 32°C; AP5 (100), CNQX (10) | ||||
| 5.5 ± 1.2 pA | GBZ (>200); control | δ | Lee and Maguire, | |
| 5.6 ± 0.7 pA | GBZ (>200); | |||
| Mouse, 8–12 week; −70 mV; high Cl− internal; 33°C; KYN (3000) | ||||
| 16.7 ± 1.7 pA | BIC (100); –70 mV | δ | Gupta et al., | |
| 0.18 ± 0.04 pA/pF | BIC (100); 0 mV | |||
| 22.5 ± 6.7 pA | Rat (Wistar); high Cl− internal; 33°C; KYN (3000) | |||
| 9.81 ± 1.51 pA | GABA (5) + BIC (100-200) | α1βδ | Glykys et al., | |
| Mouse (C57/Bl6), 1–4 month male; –70 mV; high Cl− internal; 32–34°C; KYN (3000) | ||||
| 12.2 ± 1.68 pA | GABA (5) + BIC | δ, α5 | Glykys et al., | |
| Mouse (C57Bl/6), >35d male; –70 mV; high Cl− internal; 32–34°C; KYN (3000) | ||||
| 13.3 ± 1.9 pA | GBZ (>200); control | δ | Lee and Maguire, | |
| 3.5 ± 1.3 pA | GBZ (>200); | |||
| Mouse, 8–12 week; −70 mV; high Cl− internal; 33°C; KYN (3000) | ||||
| Hilus | ||||
| 5.7 ± 0.9 pA | GBZ (10) | δ | Yu et al., | |
| Rat (Wistar), 4–5 week male; –70 mV; high Cl− internal; 33°C; KYN (3000) | ||||
| 0.5 ± 0.9 pA, n.s. | GBZ (10) | Yu et al., | ||
| Rat (Wistar), 4–5 week male; –70 mV; high Cl− internal; 33°C; KYN (3000) | ||||
| CA3 | ||||
| 30.1 ± 5.28 pA | GABA (5) + BIC | δ, α5 | Glykys et al., | |
| Mouse (C57Bl/6), >35 day male; –70 mV; high Cl− internal; 32–34°C; KYN (3000) | ||||
| 18.8 ± 4.2 pA | GBZ (20) | δ | Mann and Mody, | |
| Mouse (C57Bl/6), 4–12 week male; –70 mV; high Cl− internal; 32–34°C; KYN (3000) | ||||
| CA1 | ||||
| 35.1 ± 9.9 pA | BIC (10) | Bai et al., | ||
| 3.5 ± 1.7 pA, n.s. | GBZ (20) | |||
| Rat (Wistar), 2–3 week; high Cl− internal; −60 mV; 31°C; AP5 (40), CNQX (10), TTX (0.5) | ||||
| −0.9 ± 1.5 pA, n.s. | PTX (100) | Semyanov et al., | ||
| −0.2 ± 3.0 pA, n.s. | BIC (10) | |||
| −3.6 ± 3.7 pA, n.s. | GBZ (0.5) | |||
| Guinea pig, 3–4 week; –60 mV; high Cl− internal; 23–25°C; KYN (3000), NBQX (50), AP5 (50), MSOP (100), CGP52432 (5) | ||||
| 34.5 ± 9.6 pA | BIC (100) | α5 | Caraiscos et al., | |
| Mouse (mixed), 18–23 day male; –60 mV; high Cl− internal; 35°C; KYN (2000) | ||||
| 17.1 ± 5.5 pA | PTX (100) | δ | Scimemi et al., | |
| Rat (Sprague–Dawley), 8–10 week male; –60 mV; high Cl− internal; 23–25°C; NBQX (25), AP5 (50), CGP52432 (5) | ||||
| 38.9 ± 5.10 pA | GABA (5) + BIC | α5, δ | Glykys et al., | |
| Mouse (C57Bl/6), >35 day male; –70 mV; high Cl− internal; 32–34°C; KYN (3000) | ||||
| 8.7 ± 2.4 pA | GBZ (>200); control | δ | Lee and Maguire, | |
| 26.5 ± 6.7 pA | GBZ (>200); | |||
| Mouse, 8–12 week; –70 mV; high Cl− internal; 33°C; KYN (3000) | ||||
| 16 ± 4 pA | PTX (100) | γ | Semyanov et al., | |
| 21 ± 10 pA | BIC (10) | |||
| −5.6 ± 5.7 pA, n.s. | GBZ (0.5) | |||
| Guinea pig, 3–4 week; −60 mV; high Cl− internal; 23–25°C; KYN (3000), NBQX (50), AP5 (50), MSOP (100), CGP52432 (5) | ||||
| 0.62 ± 0.16 nS | PTX (100) | Song et al., | ||
| Mouse (C57Bl/6), 4–6 week male; high Cl− internal; 34°C; NBQX (25), AP5 (50), CGP52432 (5) | ||||
| 23.2 ± 6.1 pA | GBZ (>200); control | δ | Lee and Maguire, | |
| 3.7 ± 1.2 pA | GBZ (>200); | |||
| Mouse, 8–12 week; –70 mV; high Cl− internal; 33°C; KYN (3000) | ||||
| 30 ± 5 pA | PTX (100) | γ | Semyanov et al., | |
| Guinea pig, 3–4 week; –60 mV; high Cl− internal; 23–25°C; KYN (3000), NBQX (50), AP5 (50), MSOP (100), CGP52432 (5) | ||||
| Subiculum | ||||
| 5.32 ± 0.88 pA/pF | PTX (100) | α5, δ | Curia et al., | |
| Mouse (C57Bl/6), 4–24 week male; –70 mV; high Cl− internal; room temperature; CPP (10), CNQX (10), KYN (2000), CGP55845 (4) | ||||
| 1.75 ± 0.27 pA/pF | PTX (100) | Panuccio et al., | ||
| Rat (Sprague–Dawley), 2–3 month male; –70 mV; high Cl− internal; 21°C; CNQX (10), CPP (10), CGP55845 (4) | ||||
| 0.58 ± 0.16 pA/pF | PTX (100) | Panuccio et al., | ||
| Rat (Sprague–Dawley), 2–3 month male; –70 mV; high Cl− internal; 21°C; CNQX (10), CPP (10), CGP55845 (4) | ||||
| 0.6 ± 0.12 pA/pF | PTX (100) | Panuccio et al., | ||
| Rat (Sprague–Dawley), 2–3 month male; –70 mV; high Cl− internal; 21°C; CNQX (10), CPP (10), CGP55845 (4) | ||||
| 100 ± 16 pS | BIC (10) | Brickley et al., | ||
| Rat (Sprague–Dawley), 14 day; –70 mV; high Cl− internal; 22–25°C; CNQX (5), AP5 (10), strychnine (0.3) | ||||
| 0.01 ± 0.3 pA/pF | BIC (10); 7–8 day male | Wall and Usowicz, | ||
| 3.5 ± 0.6 pA/pF | BIC (10); 10–14 day male | |||
| 3.4 ± 0.5 pA/pF | BIC (10); 20–25 day male | |||
| 8.7 ± 1.3 pA/pF | BIC (10); 40–49 day male | |||
| Rat (Wistar); –70 mV; high Cl− internal; 22–24°C | ||||
| ~20 pS/pF | GBZ (10); 7 day male | α6 | Brickley et al., | |
| ~60 pS/pF | GBZ (10); 14 day male | |||
| ~130 pS/pF | GBZ (10); 35 day male | |||
| Mouse (mixed); –70 mV; high Cl− internal; 23–25°C | ||||
| 49.7 ± 7.5 pS/pF | NO-711 (10) + GBZ (100–200) | δ | Stell et al., | |
| Mouse (C57Bl/6), 30–181 day male; –70 mV; high Cl− internal; 20–22°C; KYN (3000–5000) | ||||
| 126 ± 24 pS/pF | GBZ (40) | Houston et al., | ||
| Mouse (C57Bl/6), 4–6 week male; –60 mV; high Cl− internal; room temperature; CNQX (5) | ||||
| n.s. | BIC (10) | Wall and Usowicz, | ||
| Rat (Wistar), adult male; –70 mV; high Cl− internal; 22–24°C | ||||
| n.s. | BIC | Harvey et al., | ||
| n.s. | TPMPA | |||
| 48 ± 10 pA | NO-711 (40) + SNAP-5114 (50) + BIC (10) Mouse (TO), 3–5 week male; –70 mV; high Cl− internal; 20–24°C; CGP55845 | |||
| Layer 1 | ||||
| ~50 pA | BIC (20) | Keros and Hablitz, | ||
| Rat (Sprague–Dawley), 17–22 day male; –65 mV; high Cl− internal; 32–35°C; CNQX (10), AP5 (20), SCH50911 (10) | ||||
| Layer 2/3 | ||||
| (frontoparietal cortex) | 1.2 ± 0.9 pA | GBZ (>100) | α4βδ | Drasbek and Jensen, |
| 26.6 ± 3.6 pA | GABA (0.8) + NO-711 (10) + GBZ (>100) | |||
| 43.2 ± 4.7 pA | THIP (1) + GBZ (>100) | |||
| Mouse (C57Bl/6), 13–19 day male; –70 mV; high Cl− internal; 33–34°C; KYN (3000) | ||||
| (frontoparietal cortex) | 66.2 ± 19.0 pA | THIP (1) + GBZ (>100) | Vardya et al., | |
| 26.5 ± 3.5 pA | GABA (0.8) + NO-711 (10) + PTX (100) | |||
| Mouse (SST-GFP), 14–24 day male; –70 mV; high Cl− internal; 33°C | ||||
| (somatosensory cortex) | 2.2 ± 0.8 pA | GBZ (0.5) | Bragina et al., | |
| 4.3 ± 1.1 pA | PTX (100) | |||
| Mouse (C57Bl/6), 2 month; –70 mV; high Cl− internal; 33–34°C; DNQX (20), CPG55845 (1) | ||||
| (motor cortex) | 8.05 ± 0.80 pA/pF | GBZ (>100); +10 mV | α5, δ | Clarkson et al., |
| 3.66 ± 1.21 pA/pF | GBZ (>100); –70 mV | |||
| Mouse (C57Bl/6), 2–4 month male; high Cl− internal; 32–34°C; KYN (3000) | ||||
| (visual cortex) | 2.4 ± 1.2 pA, n.s. | BIC (10); 3 week | Jang et al., | |
| 12.4 ± 1.2 pA | BIC (10); 5 week | |||
| 10.1 ± 1.3 pA | BIC (10); 8 week | |||
| Rat (Sprague–Dawley); –75 mV; high Cl− internal; 32–33°C; DNQX (20), AP5 (50), CGP52432 (1) | ||||
| 7.8 ± 0.8 pA | THIP (1) + GBZ (>100) | Vardya et al., | ||
| 5.6 ± 2.3 pA | GABA (0.8) + NO-711 (10) + PTX (100) | |||
| Mouse (SST-GFP), 14–24 day male; –70 mV; high Cl− internal; 33°C | ||||
| 8 ± 3 pA | GABA (5) + GBZ (10) | δ | Olah et al., | |
| Rat (Wistar), 22–35 day; –51 mV; low Cl− internal; 35°C; CGP35348 (40) | ||||
| Layer 4 (barrel cortex) | ||||
| 0.20 ± 0.02 pA/pF | PTX (100) | δ | Urban-Ciecko et al., | |
| Mouse (Swiss), 5–7 week female; –75 mV; high Cl− internal; 32°C | ||||
| 0.71 ± 0.09 pA/pF | PTX (100) | δ | Urban-Ciecko et al., | |
| Mouse (Swiss), 5–7 week female; –75 mV; high Cl− internal; 32°C | ||||
| 1.3 ± 0.13 pA/pF | PTX (100) | δ | Urban-Ciecko et al., | |
| Mouse (Swiss), 5–7 week female; –75 mV; high Cl− internal; 32°C | ||||
| Layer 5 | ||||
| (frontoparietal cortex) | 30.1 ± 3.5 pA | THIP (1) + GBZ (>100) | δ | Drasbek and Jensen, |
| Mouse (C57Bl/6), 13–19 day male; –70 mV; high Cl− internal; 33–34°C; KYN (3000) | ||||
| (frontal cortex) | 24.4 ± 6.5 pA | PTX (50); WT | Nishikawa et al., | |
| 13.3 ± 5.5 pA | PTX (50); GAD65−/− | |||
| Mouse, 12–16 week male; 0 mV; low Cl− internal; 22–24°C | ||||
| BLA | ||||
| 18.6 ± 2.9 pA | BIC (10) | Wu et al., | ||
| Mouse (C57Bl/6), 6–10 week male; –70 mV; low Cl− internal; room temperature | ||||
| 20.0 ± 5.2 pA | GBZ (100) | δ | Olmos-Serrano et al., | |
| Mouse (FVB), 20–30 day male; –60 mV; high Cl− internal; 21–23°C; DNQX (20), AP5 (50), baclofen (1) | ||||
| 0.215 ± 0.024 pA/pF | BIC (25) | α3βγ2 | Marowsky et al., | |
| Mouse (C57Bl/6), 21–49 day male; –70 mV; high Cl− internal; 32–34°C; KYN (2500), CGP54626 (0.5) | ||||
| LA | ||||
| 0.105 ± 0.027 pA/pF | BIC (25) | Marowsky et al., | ||
| (70%) | Mouse (C57Bl/6), 21–49 day male; –70 mV; high Cl− internal; 32–34°C; KYN (2500), CGP54626 (0.5) | |||
| Interneurons | ||||
| 0.143 ± 0.014 pA/pF | BIC (25) | Marowsky et al., | ||
| Mouse (GAD67-GFP), 21–49 day male; –70 mV; high Cl− internal; 32–34°C; KYN (2500), CGP54626 (0.5) | ||||
| 0.160 ± 0.02 pA/pF | BIC (25) | Marowsky et al., | ||
| Mouse (GAD67-GFP), 21–49 day male; –70 mV; high Cl− internal; 32–34°C; KYN (2500), CGP54626 (0.5) | ||||
| CeA | ||||
| 19.7 ± 2.4 pA | GBZ (100) | α1 | Herman et al., | |
| 19.0 ± 3.1 pA | PTX (100) | |||
| Mouse (CRF1-GFP), 2–6 month male; –60 mV; high Cl− internal; room temperature; DNQX (20), AP5 (50), CGP55845 (1) | ||||
| −1.8 ± 2.7 pA, n.s. | GBZ (100) | δ | Herman et al., | |
| Mouse (CRF1-GFP), 2–6 month male; –60 mV; high Cl− internal; room temperature; DNQX (20), AP5 (50), CGP55845 (1) | ||||
| 1.7 ± 0.8 pA | BIC (25); 22–24°C | α5β3γ2 | Ade et al., | |
| 3.0 ± 1.7 pA | GBZ (10); 22–24°C | |||
| 1.6 ± 1.3 pA | BIC (25) or GBZ (10); 31°C | |||
| Mouse (D2-EGFP), 15–25 day; –70 mV; high Cl− internal | ||||
| 36.5 ± 8.9 pA | GABA (5) + BIC (100) | δ | Santhakumar et al., | |
| Mouse (D2-EGFP), >30 day male; –70 mV; high Cl− internal; 34°C; AP5 (10), DNQX (25) | ||||
| 18.9 ± 0.3 pA | BIC (25); 22–24°C | α5β3γ2 | Ade et al., | |
| 16.0 ± 1.2 pA | GBZ (10); 22–24°C | |||
| 30.4 ± 5.5 pA | BIC (25) or GBZ (10); 31°C | |||
| Mouse (D2-EGFP), 15–25 day; –70 mV; high Cl− internal | ||||
| 6.2 ± 2.0 pA | GABA (5) + BIC (100) | δ | Santhakumar et al., | |
| Mouse (D2-EGFP), >30 day male; –70 mV; high Cl− internal; 34°C; AP5 (10), DNQX (25) | ||||
| VB | ||||
| 16.5 ± 2.0 pA | BIC (20) | α4β2δ | Jia et al., | |
| Mouse (C57Bl/6), 12–20 day; –65 mV; high Cl− internal; 20–22°C; KYN (3000–5000) | ||||
| 17.6 ± 13.4 pA (62.5%) | GBZ (50) | Cope et al., | ||
| Rat (Wistar), 14–21day; –70 mV; high Cl− internal; 32°C; KYN (3000) | ||||
| RTN | n.s. | BIC (20) | Jia et al., | |
| Mouse (C57Bl/6), 12–20 day; –65 mV; high Cl− internal; 20–22°C; KYN (3000–5000) | ||||
| dLGN | ||||
| 16.4 ± 13.7 pA (75%) | GBZ (50) | δ | Cope et al., | |
| Rat (Wistar), 14–21 day; –70 mV; high Cl− internal; 32°C; KYN (3000) | ||||
| 54.2 ± 13.9 pS/pF | GBZ (20) | δ | Bright et al., | |
| Mouse (C57Bl/6), >1 month; –60 mV; high Cl− internal; 35–38°C; KYN (500) | ||||
| 6.7 ± 4.5 pS/pF, n.s. | GBZ (20) | Bright et al., | ||
| Mouse (C57Bl/6), >1 month; –60 mV; high Cl− internal; 35–38°C; KYN (500) | ||||
| vLGN | ||||
| 6.6 ± 4.1 pS/pF, n.s. | GBZ (20) | Bright et al., | ||
| Mouse (C57Bl/6), >1 month; –60 mV; high Cl− internal; 35–38°C; KYN (500) | ||||
| 2.5 ± 0.9 pS/pF, n.s. | GBZ (20) | Bright et al., | ||
| Mouse (C57Bl/6), >1 month; –60 mV; high Cl− internal; 35–38°C; KYN (500) | ||||
| dMGB | ~22 pA | GBZ (50); 3–8 month | α4δ | Richardson et al., |
| ~9 pA | GBZ (50); 28–32 month | |||
| Rat (FBN), male; –60 mV; high Cl− internal; 22°C; DNQX (10), AP5 (50) | ||||
| vMGB | ~25 pA | GBZ (50); 3–8 month | α4δ | Richardson et al., |
| ~6 pA | GBZ (50); 28–32 month | |||
| Rat (FBN), male; –60 mV; high Cl− internal; 22°C; DNQX (10), AP5 (50) | ||||
| SON | ||||
| 20.20 ± 2.54 pA | BIC (20) or PTX (100–300); 22–24°C | α5βγ2 | Park et al., | |
| 19.8 ± 2.7 pA | BIC (20) or PTX (100–300); 35°C | |||
| n.s. | GBZ (1–300); 22–24°C | |||
| Rat (Wistar, Sprague–Dawley), >5 week male; –70 mV; high Cl− internal; AP5 (100), CNQX (10) | ||||
| PVN | ||||
| 9.79 ± 1.28 pA | BIC (20); room temperature | δ | Park et al., | |
| 11.38 ± 0.57 pA | BIC (20); 35°C | |||
| n.s. | GBZ (0.1–100) | |||
| Rat (Wistar), male; –70 mV; high Cl− internal | ||||
| 11.2 ± 2.5 pA | GBZ (>200) | δ | Sarkar et al., | |
| 20.9 ± 2.5 pA | THDOC (0.01) + GBZ (>200) | |||
| Mouse (C57Bl/6, CRH-GFP), 3 month male; –70 mV; high Cl− internal; 33°C; KYN (3000) | ||||
| 13.8 ± 3.4 pA | GBZ (>200); control | δ | Lee et al., | |
| 0.7 ± 0.2 pA | GBZ (>200); | |||
| Mouse, 8–12 week male; –70 mV; high Cl− internal; 33°C; KYN (3000) | ||||
| Preoptic area | 7.7 ± 4.3 pA | L-655, 708 (50); male | α5 | Penatti et al., |
| 10.4 ± 2.0 pA (73%) | L-655, 708 (50); female | |||
| Mouse (C57Bl/6), 13 week; –70 mV; high Cl− internal; 20–22°C; KYN (2000) | ||||
| 3.83 ± 0.97 pA | PTX (100); male | Penatti et al., | ||
| ~3 pA (50%) | PTX (100); female | |||
| Mouse (GnRH-GFP), 8 week; –70 mV; high Cl− internal; 20–22°C; KYN (2000) | ||||
| 17.0 ± 3.2 pA (56%) | PTX (300) | δ | Bhattarai et al., | |
| 13.1 ± 3.1 pA (44%) | BIC (20) | |||
| Mouse (GnRH-GFP), 6–76 day; –60 mV; high Cl− internal; room temperature; KYN (2000) | ||||
| TMN | ||||
| n.s. | BIC (20) | Zecharia et al., | ||
| GBZ (20) | ||||
| Mouse, 8–12 week male; –60 mV; high Cl− internal; 21–22°C; KYN (1000), strychnine (1000) | ||||
| Perifornical area | ||||
| n.s. | BIC (20) | Zecharia et al., | ||
| GBZ (20) | ||||
| Mouse, 8–12 week male; –60 mV; high Cl− internal; 21–22°C; KYN (1000), strychnine (1000) | ||||
| 9.2 ± 4.7 pA, n.s. | GBZ (20) | δ | Numata et al., | |
| 104.3 ± 20.9 pA | GABA (5) + SKF89976A (30) + SNAP-5114 (50) + BIC (20) | |||
| Mouse, 3–15 day; –70 mV; high Cl− internal; 30°C; DNQX (10), AP5 (50), strychnine (1), CGP55845 (1), TTX (1) | ||||
| 20.9 ± 2.3 pA | BIC (100); –70 mV, high Cl− internal | αβδ, αβε | Chesnoy-Marchais, | |
| 26.0 ± 12.7 pA | BIC (100); –10 mV, low Cl− internal | |||
| 26.1 ± 7.0 pA | PTX (100); –70 mV, high Cl− internal | |||
| Rat (Sprague–Dawley), 11–15 day; 23–26°C; KYN (1000), strychnine (1) | ||||
| Locus coeruleus | ||||
| n.s. | BIC (20) | Zecharia et al., | ||
| GBZ (20) | ||||
| Mouse, 8–12 week male; –60 mV; high Cl− internal; 21–22°C; KYN (1000), strychnine (1000) | ||||
| Dorsal horn | ||||
| 650 ± 90 pA/nF (67.1%) | BIC (100) | α5βγ2, α4βδ, αβε | Takahashi et al., | |
| Mouse (ddY), 3–9 week male; 0 mV; low Cl− internal; 36°C; strychnine (2), TTX (0.5) | ||||
| 8.4 ± 0.7 pA | BIC (20) | Ataka and Gu, | ||
| Mouse, 6–9 week; 0 mV; low Cl− internal; 22°C | ||||
| n.s. | BIC (30) | Mitchell et al., | ||
| Rat (Sprague–Dawley), 15–21 day; –60 mV; high Cl− internal; 35°C; KYN (2000), TTX (0.5) | ||||
| 1.5 ± 1.3 pA, n.s. | GBZ (1) | Maeda et al., | ||
| 8.0 ± 1.1 pA (79%) | BIC (20) | |||
| 9.5 ± 3.2 pA (75%) | GBZ (1) + BIC (20) | |||
| 65.92 ± 21.6 pA | GABA (1000) + BIC (20) | |||
| Rat (Sprague–Dawley), 6–8 week male; 0 mV; low Cl− internal; 36°C; strychnine (2) | ||||
| 0.60 ± 0.16 pA/pF (80%) | GABA (5) + BIC (20) | δ | Bonin et al., | |
| Mouse, 3–4 month male; 0 mV; high Cl− internal; 36°C; CNQX (10), TTX (0.3) | ||||
| ~3 pA | BIC (10); 16–18 day | Takazawa and MacDermott, | ||
| ~6 pA | BIC (10); 29–32 day | |||
| Mouse (GAD67-EGFP); 0 mV; low Cl− internal; 32°C | ||||
| ~6 pA | BIC (10); 16–18 day | Takazawa and MacDermott, | ||
| ~1 pA | BIC (10); 29–32 day | |||
| Mouse (GAD67-EGFP); 0 mV; low Cl− internal; 32°C | ||||
| Lateral horn (Intermediolateral cell column) | ||||
| n.s. | BIC (2–100); resting potential, low Cl− internal | α5βγ2 | Wang et al., | |
| 2.4 ± 0.4 mV | BIC (100); resting potential, high Cl− internal | |||
| 4.4 ± 0.5 mV | BIC (100); 0 mV, low Cl− internal | |||
| 4.0 ± 1.4 mV | PTX (100); 0 mV, low Cl− internal | |||
| n.s. | GBZ (0.025–25); resting potential or 0 mV, low Cl− internal | |||
| Rat, 10–15 day; room temperature; KYN (2000) | ||||
| n.s. | BIC (100); 0 mV, low Cl− internal | Wang et al., | ||
| Rat, 10–15 day; room temperature; KYN (2000) | ||||
| Ventral horn | 9.6 ± 2.8 pA | BIC (25) | Chub and O'Donovan, | |
| Chick (White Leghorn), E10–11; –70 mV; high Cl− internal; 28°C; TTX (1), AP5 (50), CNQX (10) | ||||
| 24.3 ± 10.3 pA | GBZ (500) | α4βδ | Labarrera et al., | |
| Mouse (C57Bl/6), 25–30 day female; +20 mV; low Cl− internal; | ||||
| n.s. | BIC (20) | Hull et al., | ||
| ~42 pA | TPMPA (150) | |||
| Goldfish ( | ||||
| ~22 pA | PTX (50) | ρ1, ρ2 | Palmer, | |
| ~16 pA | TPMPA (50) | |||
| n.s. | BIC (50) | |||
| Goldfish ( | ||||
| −2.3 ± 3 pA, n.s. | GBZ (5); Rat (Sprague–Dawley), 1–7 day | Wang et al., | ||
| −0.5 ± 2.0 pA, n.s. | GBZ (5); Mouse (C57Bl/6), 0–7 day | |||
| –60 mV; high Cl− internal; 32–34°C | ||||
| 48.7 ± 16 pA | GBZ (5); Mouse (IL2RA-GFP), 5–7 day | δ | Wang et al., | |
| –60 mV; high Cl− internal; 32–34°C | ||||
Magnitude of tonic current as measured in slice electrophysiology with the animals, recording conditions, and antagonists used. GABA.
BLA, basolateral amygdala; CeA, central amygdala; CRH, corticotropin-releasing hormone; FS, fast-spiking; GnRH, gonadotropin-releasing hormone; LA, lateral amygdala; LGN, lateral geniculate nucleus; LTS, low-threshold spiking; MGB, medial geniculate body; ML, molecular layer; PVN, paraventricular nucleus; RS, regular-spiking; RTN, reticular thalamic nucleus; RVLM, rostral ventrolateral medulla; SON, supraoptic nucleus; SST, somatostatin; TC, thalamocortical; TMN, tuberomammillary nucleus; VB, ventrobasal thalamic nucleus.
Parenthesis denotes percentage of cells exhibiting a tonic conductance; n.s., not significant.
BIC, bicuculline; CNQX, 6-cyano-7-nitroquinoxaline-2,3-dione; CPP, 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; DNQX, 6,7-dinitroquinoxaline-2,3-dione; GBZ, gabazine (SR95531); KYN, kynurenic acid; MCPG, α-methyl-4-carboxyphenylglycine; MSOP, α-methylserine-O-phosphate; NBQX, 2,3,-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione; PTX, picrotoxin; PTZ, pentylenetetrazol; THIP, 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol; TPMPA, (1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid; TTX, tetrodotoxin.
Figure 1Extrasynaptic GABA. Interneurons regulate the activity of principal cells through GABAergic transmission, but are in turn regulated by GABAergic input from other interneurons. This additional level of GABAergic signaling introduces complexity to understanding neuronal excitability and its modulation. For example, neurosteroids can act on GABAARs, especially extrasynaptic receptors that contain a δ subunit, to potentiate GABAergic inhibition on principal neurons and diminish their excitability. Simultaneously, neurosteroids can potentiate GABAergic inhibition on interneurons, thus disinhibiting the principal neurons and enhancing their excitability. These opposing effects, combined with the variability in GABAergic inhibition across cell types and brain regions, present complications when considering GABAARs as therapeutic targets.